From March 25-28, 2023, gynecologic cancer experts from around the world converged on Tampa, Florida to participate in the Annual Meeting on Women’s Cancer hosted by the Society of Gynecologic Oncology. The meeting was packed with educational and scientific sessions highlighting the latest in the care of patients with gynecologic cancers. Below are some highlights of … Continued
A new study, published in the Journal of Clinical Investigation and funded in part by OCRA, has found that mesothelial cells are a critical factor in ovarian cancer metastasis. High-grade serous ovarian cancer, the most common ovarian cancer subtype, is known to be aggressive, and is associated with the presence of ascites and widespread metastases … Continued
We hope you’re feeling the love from the teal community this week, and always. We’re just seven weeks into 2023 and there’s so much to share — new grantees, a new website, and a bold, new direction in the fight against ovarian cancer. Research Advocacy Patient Support Ways to Give Did you know there are three simple ways … Continued
Ovarian cancer is not a single disease, but rather a group of diseases classified by type and subtype. And while they all affect the ovaries, they are quite unique in terms of origin and prognosis. High-grade serous ovarian cancer (HGSOC) is the most common subtype, accounting for the majority of diagnoses, and typically involving a first-line … Continued
OCRA is pleased to award $7 million in ovarian cancer research funding for 2023, representing the largest annual research investment in our history. With this funding, 20 cancer researchers at 15 medical institutions across the country will pursue projects that break new ground in the fight against this disease. Selected by OCRA’s Scientific Advisory Committee for their potential … Continued
An article published on February 2nd in The Washington Post highlights a turning point in our fight against ovarian cancer. As covered in the article, “Fallopian tube removal advised for more women to prevent ovarian cancer,” OCRA released a consensus statement, endorsed by the Society of Gynecologic Oncology, encouraging an aggressive prevention strategy: removal of the fallopian … Continued
An article published on February 1st in The New York Times highlights a turning point in our fight against ovarian cancer. As covered in the article, “To Prevent Cancer, More Women Should Consider Removing Fallopian Tubes, Experts Say,” OCRA is launching an important campaign centered around two messages with proven outcomes: knowing one’s risk, and … Continued
Today marks a turning point in our fight against ovarian cancer. As covered in The New York Times, we are launching an important campaign centered around two messages with proven outcomes: knowing one’s risk, and taking preventative action. You know better than anyone the challenges we face in the fight against ovarian cancer. There’s no … Continued
Finding a method of early detection for ovarian cancer has been a primary focus of research for years, and was believed to be a promising approach to stopping women, or anyone born with ovaries, from dying of the disease. Some other cancers have demonstrated that earlier stage diagnoses can lead to better prognoses, and an oft-cited … Continued
OCRA is pleased to award research prizes to Dr. Ursula Matulonis and Dr. Pradeep Chaluvally-Raghavan, two investigators doing groundbreaking and important work in the field of ovarian cancer research. OCRA’s research prize recipients are selected by members of OCRA’s Scientific Advisory Committee. These prizes were awarded in December 2022. Dr. Ursula Matulonis Awarded Rosalind Franklin … Continued
A recent study, funded in part by OCRA, has shed new light on how the most common subtype of ovarian cancer develops and metastasizes, by identifying a key molecule that allows malignancies in the fallopian tube to migrate to the ovaries and continue to grow. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype … Continued
As immunotherapies have seen rising success in treating several other cancers, researchers are hard at work uncovering why immunotherapy for ovarian cancer has, so far, proven ineffective. In a study published in Nature, a research team at Memorial Sloan Kettering Cancer Center set out to identify specific factors that lead to immune evasion in high-grade … Continued
Get email updates about research news, action alerts, and ways to join the fight.
